There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ObsEva SA (OBSV) and Urogen Pharma Ltd (URGN) with bullish sentiments.
ObsEva SA (OBSV)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on ObsEva SA today and set a price target of $44. The company’s shares closed on Friday at $13.89.
Selvaraju wrote:
“We feel that this long-term durability of effect should bode well for the future of linzagolix in endometriosis. In anticipation of further progress in 2019 with linzagolix, nolasiban and OBE022, we reiterate our Buy rating and 12-month target of $44 per share. Bone mineral density appears to be reverting to baseline. Changes in bone mineral density (BMD) from baseline to week 52—measured by dual-energy x-ray absorptiometry (DXA) scan—were consistent with the values observed at 24 weeks of treatment. In our view, these data—along with the pain relief efficacy observed long-term—further support the dose selection for the Phase 3 program in women with endometriosis-associated pain (i.e., linzagolix 75mg once-daily dose without add- back hormonal therapy (ABT), and 200mg once-daily dose in combination with low-dose ABT).”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 0.9% and a 37.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
ObsEva SA has an analyst consensus of Strong Buy, with a price target consensus of $33.40, which is a 140.5% upside from current levels. In a report issued on April 30, Wedbush also reiterated a Buy rating on the stock with a $37 price target.
See today’s analyst top recommended stocks >>
Urogen Pharma Ltd (URGN)
In a report released today, Leland Gershell from Oppenheimer assigned a Buy rating to Urogen Pharma Ltd, with a price target of $70. The company’s shares closed on Friday at $36.37, close to its 52-week low of $34.61.
Gershell observed:
“Incremental OLYMPUS data as presented yesterday at the AUA conference continue to illustrate UGN-101’s potential as a non-surgical option for low-grade upper tract urothelial carcinoma. A final 59% CR rate at the primary evaluation is consistent with interim reveals, and maturing follow-up data indicate broad durability of response to at least six months. Efficacy in the unresectable subset (~half of those enrolled) differed little from that in the overall trial population. UGN-101’s rolling NDA continues toward completion and we expect a 1H20 launch into this initial $500M+ peak sales opportunity. Later this year, we anticipate a first look from UGN-102’s Phase 2b trial in LG NMIBC as well as data from BotuGel’s POC trial in OAB (w/partner AGN).”
According to TipRanks.com, Gershell is a 4-star analyst with an average return of 17.5% and a 58.2% success rate. Gershell covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Anchiano Therapeutics Ltd, and Miragen Therapeutics Inc.
Currently, the analyst consensus on Urogen Pharma Ltd is a Strong Buy with an average price target of $65, implying a 78.7% upside from current levels. In a report issued on April 24, H.C. Wainwright also reiterated a Buy rating on the stock with a $75 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
